Front Oncol: Effectiveness and safety of Anlotinib in the treatment of Chinese patients with recurrent or metastatic cervical cancer

Cervical cancer (CC) is one of the most common gynecological cancers and ranks fourth in global female morbidity and mortality
.

The response rate of second-line or above treatment is relatively low, ranging from 15% to 30% , and the response duration of recurrent or metastatic CC is short

Cervical cancer (CC) is one of the most common gynecological cancers and ranks fourth in global female morbidity and mortality

The study included advanced CC patients whose recurrence or metastasis was confirmed by histology
.

The patient took 12 mg of Anlotinib orally before breakfast every day for 2 weeks and rested for 1 week (every 3 weeks (21 days) as a cycle)

The study included advanced CC patients whose recurrence or metastasis was confirmed by histology

From September 2018 to November 2019, a total of 46 patients were screened , of which 41 patients with recurrent advanced CC were selected for this study

During the 16 -month follow-up period, 10 patients (24.

PFS and OS

PFS and OS PFS and OS

Forty patients (40/41) were evaluated for treatment response
.

None of the patients achieved CR, and 10 (24.

Forty patients (40/41) were evaluated for treatment response

Efficacy evaluation

Efficacy assessmentEfficacy assessment

The analysis of ORR subgroups stratified by clinicopathological characteristics showed that there was tumor regression in all subgroups, and the ORR of each subgroup was consistent with the overall
.

The analysis of ORR subgroups stratified by clinicopathological characteristics showed that there was tumor regression in all subgroups, and the ORR of each subgroup was consistent with the overall
.

The analysis of ORR subgroups stratified by clinicopathological characteristics showed that there was tumor regression in all subgroups, and the ORR of each subgroup was consistent with the overall

Subgroup ORR analysis

Subgroup ORR analysis Subgroup ORR analysis

All patients experienced AEs
.

Most AEs is 1 stages or 2 Ji

All patients experienced AEs

Adverse events

                   Adverse events  Adverse events

In summary, research shows that this is the first study to evaluate the effectiveness and safety of Anlotinib in patients with recurrent or metastatic cervical cancer in China
.
Anlotinib has produced a long-lasting clinical response in these patients, and its safety is controllable
.

In summary, research shows that this is the first study to evaluate the effectiveness and safety of Anlotinib in patients with recurrent or metastatic cervical cancer in China .
Anlotinib has produced a long-lasting clinical response in these patients, and its safety is controllable .
In summary, the research shows that the research shows that this is the first study to evaluate the effectiveness and safety of Anlotinib in patients with recurrent or metastatic cervical cancer in China .
Anlotinib has produced a long-lasting clinical response in these patients, and its safety is controllable .
This is the first study to evaluate the effectiveness and safety of Anlotinib in patients with recurrent or metastatic cervical cancer in China
.
Anlotinib has produced a long-lasting clinical response in these patients, and its safety is controllable
.

Original source:

Original source:

Zhu J, Song C, Zheng Z, Xia L, Chen Y, Ke G and Wu X (2021) Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Front.
Oncol.
11:720343.
doi: 10.
3389/fonc.
2021.
720343

Zhu J, Song C, Zheng Z, Xia L, Chen Y, Ke G and Wu X (2021) Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial.
Front.
Oncol.
11:720343.
doi: 10.
3389/fonc.
2021.
720343 leave a message here